Declaration of Financial/Propriety Interest
2016

Research/Grants:
National Institutes of Health (NIH)

Consulting (last three years):
Xhale, Takeda, Mitsubishi Tanabe Pharma Development America, Taisho Pharmaceutical Inc., Lundbeck, Prismic Pharmaceuticals, Clintara, Total Pain Solutions (TPS), Gerson Lehrman Group (GLG) Healthcare & Biomedical Council

Stockholder:
Xhale, Celgene, Seattle Genetics, Abbvie, Titan Pharmaceuticals, OPKO Health, Inc.

Scientific Advisory Boards:
American Foundation for Suicide Prevention (AFSP), Brain and Behavior Research Foundation (BBRF) (formerly named National Alliance for Research on Schizophrenia and Depression [NARSAD]), Xhale, Anxiety, Disorders Association of America (ADAA), Skyland Trail, Clintara. RiverMend Health LLC.

Board of Directors:
AFSP, Gratitude America, ADAA

Income sources or equity of $10,000 or more:
American Psychiatric Publishing, Xhale, Clintara, CME Outfitters, Takeda

Patents:
Method and devices for transdermal delivery of lithium (US 6,375,990B1)
Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2)

Speakers Bureau:
None